BACKGROUND: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at disproportionately high risk for anal cancer. There is no definitive approach to the management of high-grade squamous intraepithelial lesions (HSIL), which are precursors of anal cancer, and evidence suggests that posttreatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves HSIL treatment effectiveness. The objectives of this study were to evaluate the optimal HSIL management strategy with respect to clinical effectiveness and cost-effectiveness and to identify the optimal age for initiating HSIL management. METHODS: A decision analytic model of the natural history of anal carcinoma and HSIL management strategies was constructed for HIV-positive MSM who were 27 years old or older. The model was informed by the Surveillance, Epidemiology, and End Results-Medicare database and published studies. Outcomes included the lifetime cost, life expectancy, quality-adjusted life expectancy, cumulative risk of cancer and cancer-related deaths, and cost-effectiveness from a societal perspective. RESULTS: Active monitoring was the most effective approach in patients 29 years or younger; thereafter, HSIL treatment plus adjuvant qHPV vaccination became most effective. When cost-effectiveness was considered (ie, an incremental cost-effectiveness ratio [ICER] < $100,000/quality-adjusted life-year), do nothing was cost-effective until the age of 38 years, and HSIL treatment plus adjuvant qHPV vaccination was cost-effective beyond the age of 38 years (95% confidence interval, 34-43 years). The ICER decreased as the age at HSIL management increased. Outcomes were sensitive to the rate of HSIL regression or progression and the cost of high-resolution anoscopy and biopsy. CON-CLUSIONS: The management of HSIL in HIV-positive MSM who are 38 years old or older with treatment plus adjuvant qHPV vaccination is likely to be cost-effective. The conservative approach of no treatment is likely to be cost-effective in younger patients. Cancer 2017;123:4709-19.
INTRODUCTION
Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at disproportionately high risk for anal cancer. The incidence of anal cancer in HIV-positive MSM is approximately 80 times higher than the incidence in men from the rest of the general population. [1] [2] [3] A persistent infection with human papillomavirus (HPV) has been associated with the development of high-grade squamous intraepithelial lesions (HSIL), which is a precursor of anal cancer. 4 The incidence of HSIL among HIV-positive MSM (12.8 cases per 1000 person-months in 2011) increased by 12% between 2000 and 2009, [5] [6] [7] [8] [9] and the prevalence of HSIL among HIV-positive MSM is almost 50%. [10] [11] [12] [13] HSIL treatment is likely to prevent progression to invasive cancer 14 ; however, the best management of these lesions remains highly controversial. [15] [16] [17] In recent years, high-resolution anoscopy (HRA)-directed ablation with a laser, cryotherapy, an infrared coagulator, or electrocautery has been evolving into a standard approach for the management of HSIL. [18] [19] [20] [21] Studies have shown that ablation is more effective than no treatment in clearing HSIL; however, the rate of HSIL recurrence after the initial treatment is extremely high, with approximately 60% to 70% of HIV-positive MSM experiencing recurrence within 1 year of treatment. 19, [21] [22] [23] The risk of recurrence increases with each additional lesion treated, 14 and despite treatment and routine follow-up, patients are at risk of progressing to cancer. 14, 23 An alternative potential approach to managing HSIL is ablative treatment along with adjuvant quadrivalent human papillomavirus (qHPV) vaccination (ie, vaccination after treatment for HSIL). Recent studies suggest that posttreatment adjuvant qHPV vaccination improves treatment effectiveness by decreasing the risk of HSIL recurrence by approximately 50%, and it is cost-saving in comparison with treatment alone. [24] [25] [26] If not treated, HSIL can naturally regress. 27 Some suggest that HSIL treatment should be delayed and that patients should be followed until the development of anal cancer because patients, in addition to having frequent recurrences, may experience postoperative complications such as anal stenosis and fecal incontinence; thus, the risk of HSIL treatment may outweigh the benefit. 16, 17 This approach to HSIL management is known as active monitoring or watchful waiting 17, 28 and consists of periodically performing digital anorectal examination (DARE) and HRA for the early detection of anal cancer and biopsying visible lesions.
In this study, our first objective was to find the optimal strategy for managing HSIL in HIV-positive MSM with respect to clinical effectiveness and cost-effectiveness of the following approaches: do nothing, active monitoring, HSIL treatment alone, and HSIL treatment plus adjuvant qHPV vaccination. Our second objective was to identify the optimal age for initiating HSIL management.
MATERIALS AND METHODS
We developed a Markov-based state-transition model to simulate the clinical course of HIV-positive MSM diagnosed with HSIL. The model was developed from a US societal perspective over the time horizon of patients' lifetimes using annual cycles. For a detailed model description, see section A in the online supporting information.
Baseline Population
The baseline population consisted of a cohort of HIVpositive MSM (median age, 40 years; range, 27-60 years) with a first-time HSIL diagnosis in the United States. The base-case age of 40 years was chosen because the median age at HSIL diagnosis in prior studies was 40 years. 22, 29, 30 We categorized patients according to their CD4 cell count distribution (ie, >500, 200-500, or <200).
Comparators for Clinical and Economic Evaluations

Do nothing
Given that there is no uniform standard of care for HSIL, we simulated a do-nothing strategy as one potential option. The rationale for including this option was that not all patients progress to anal cancer, and progression can take several years; therefore, it might be reasonable to delay treatment until patients develop anal cancer. The diagnosis of invasive cancer was based on symptoms (typically bleeding, an anal mass, or anal pain), and the distribution of the stages of diagnosis was based on the Surveillance, Epidemiology, and End Results database. 31, 32 These patients subsequently would receive treatment for invasive cancer.
Active monitoring or watchful waiting
An alternative strategy is active monitoring or watchful waiting. We simulated active monitoring of patients with DARE and HRA-guided biopsy for the early detection of cancer. 28 Patients could progress to invasive cancer, and their stage of diagnosis was based on the work of Berry et al. 33 These patients subsequently would receive treatment for cancer.
Treatment for HSIL
The third strategy was defined as the immediate treatment of HSIL. After the initial diagnosis and treatment, these patients were monitored annually with DARE and HRA for the subsequent risk of HSIL recurrence or cancer. Long-term HSIL treatment effectiveness data in terms of the risk of recurrence after treatment for initial and subsequent HSIL were obtained from the literature (Supporting Table A. 3 [see online supporting information]). 14, [21] [22] [23] We also incorporated loss to follow-up during the annual screening and treatment for subsequent lesions. 22 Patients lost during follow-up were at risk of progressing to anal cancer.
Treatment plus adjuvant qHPV vaccination
Finally, we simulated the long-term effectiveness of providing HSIL treatment plus adjuvant qHPV vaccination. Patients who receive adjuvant qHPV vaccination are less likely to experience HSIL recurrence. 26 Vaccine effectiveness data were obtained from the literature (Supporting Table A .3 [see online supporting information]). [24] [25] [26] Original Article A detailed description of all comparators and clinical data is included in section A in the online supporting information.
Natural History and Health-State Transitions
Disease transitions occurred at 2 levels: 1) within health states for HIV and 2) within health states for anal disease. Anal carcinogenesis (ie, the probability of anal disease progression or regression) was conditional on the receipt of the form of care for HSIL, the patient's HIV status, and the receipt of antiretroviral therapy.
Disease progression from HSIL to anal cancer in patients who were not receiving treatment for HSIL or were actively being monitored was calibrated using a separate natural-history model of anal carcinogenesis that used the age-specific incidence of anal cancer in HIV-positive MSM (see section B in the online supporting information) as a calibration target. For patients receiving treatment for HSIL and subsequent HSIL recurrences, disease progression to invasive cancer was based on an estimation by Pineda et al. 23 HSIL regression data were obtained from the literature. 27 Because natural-history data on disease progression after natural regression were not available, we used the available data on the initial disease transition (Supporting Table A .2 [see online supporting information]). 5, 34, 35 Patients during their lifetime might die of HIV-related illness, anal cancer, or other unrelated causes. 32, 36 Costs and Health-Related Quality of Life Our model included the costs of HIV-related care (by CD4 count), anal cancer treatment (by stage), HSIL treatment, HRA and biopsy, and adjuvant qHPV vaccination (Supporting Table A . 4 [see online supporting information]). 32, [37] [38] [39] We converted all costs to 2016 US dollars using consumer price indices for medical care. 40 To account for the differential quality of life in different health states, we assigned health-related quality-oflife weights (utilities) to each health state using published data. Utilities were assigned on the basis of the HIV status, anal disease status, and age. 34, 41 Analysis and Model Outcomes
We followed the recommendations of the US Panel on Cost-Effectiveness in Health and Medicine for conducting our analysis. 42 For each strategy, we simulated the life expectancy, quality-adjusted life-years (QALYs), and total lifetime cost. Future costs and QALYs were reported in terms of the net present value with an annual discount rate of 3%. 43 We presented outcomes for all HIV-positive MSM as well as the subgroups stratified by the patient HIV status. A comparative assessment was conducted, and the results were presented in the form of incremental cost-effectiveness ratios (ICERs), decreases in the lifetime risk of anal cancer, and decreases in the lifetime anal cancer mortality risk. To determine the cost-effectiveness of strategies by age, we estimated outcomes by the age at the initiation of HSIL management, starting from age 27 onwards. We used the commonly recommended societal willingness-to-pay threshold of $100,000/QALY to determine the cost-effectiveness of strategies. 44 We performed comprehensive sensitivity analyses of all model parameters to evaluate the robustness of the outcomes. Deterministic (1-way and 2-way) sensitivity analyses were conducted by varying input model parameters. Finally, a probabilistic sensitivity analysis was conducted to assess decision uncertainty, and the outcomes were presented using cost-effectiveness acceptability curves.
RESULTS
Model Validation
We cross-validated our model by comparing our calibrated rates of progression from HSIL to anal cancer with those reported in previously published studies. 34, 45, 46 The model-calibrated HSIL-to-anal cancer progression rate was within the plausible range of the reported progression and followed a similar trend (ie, the rate of progression increased with increasing age).
We also compared the model-predicted cumulative risk of HSIL to the cumulative risk reported by Burgos et al. 47 The predicted natural-history HSIL risk was within the 95% confidence intervals of the reported risk. For detailed model validation, see section C in the online supporting information.
Clinical Outcomes
For 40-year-old HIV-positive MSM, compared with do nothing, treatment decreased the lifetime incidence of anal cancer and mortality by 66%, and treatment plus adjuvant qHPV vaccination decreased the lifetime incidence and mortality by 80% (Fig. 1A,B) . Active monitoring did not reduce the cumulative incidence of anal cancer; however, early detection attributed to active monitoring could decrease the lifetime mortality risk by 6%.
We further evaluated the influence of age on the optimal HSIL management strategy. We found that active monitoring was the most effective HSIL management strategy in patients up to the age of 29 years (ie, it was associated with the highest quality-adjusted life expectancy; Fig. 2A,B) . From the age of 30 years onward, the combination of treatment and qHPV vaccination was the most effective strategy.
Cost-Effectiveness Analysis
For 40-year-old HIV-positive MSM, treatment plus adjuvant qHPV vaccination was the most cost-effective strategy with a resulting ICER of $73,367/QALY (Table 1) . Active monitoring and treatment for HSIL were dominated by the treatment plus adjuvant qHPV vaccination strategy and were eliminated. 48 When we estimated the cost-effectiveness by age, we found that treatment plus adjuvant qHPV vaccination was cost-effective in patients 38 years old or older (95% confidence interval, 34-43 years; Fig. 3 ). In patients who were 37 years old or younger, do nothing was costeffective.
Sensitivity Analysis
To evaluate the sensitivity of the results to age, we identified the top 15 model parameters in the order of their impact on the minimum age at which treatment plus adjuvant qHPV vaccination became cost-effective (Fig.  4A ) and the base-case ICER (Fig. 4B) . The outcomes were most sensitive to HSIL progression and regression in untreated patients. When the age-adjusted HSIL-to-anal cancer progression was 0.01 (base case, 0.0035 or 1 of 286 per year), the management of HSIL with treatment plus qHPV vaccination was cost-effective, regardless of the age of the patients. Similarly, when the age-adjusted HSIL The strategy is both less effective and more costly than a linear combination of 2 other strategies with which it is mutually exclusive. The strategy is more costly and less effective than the next alternative.
Optimal Management of Anal HSIL/Deshmukh et al
Cancer December 1, 2017 regression was 10% (base case, 15%), then treatment plus qHPV vaccination became cost-effective at the age of 31 years. The base-case ICERs for these values were $42,054/ QALY and $49,616/QALY, respectively. The ICER was not sensitive to HSIL treatment effectiveness and vaccine efficacy because it did not exceed $100,000/QALY even when a high recurrence rate and worst-case adjuvant qHPV vaccination efficacy were assumed (Supporting Table D.1 [see online supporting  information] ). An additional 1-way sensitivity analysis of natural-history and cost parameters is presented in Supporting Table D. 2 (see online supporting information). The ICER changed marginally for the subgroups of patients presenting with CD4 cell count distributions of >500, 200 to 500, and <200. For all subgroups, treatment plus adjuvant qHPV vaccination remained costeffective.
A 2-way sensitivity analysis demonstrated that the cost-effective strategy changed with the change in HSILto-anal cancer progression in untreated (base case, 0.0035) and treated patients (base case, 0.0012; Supporting Fig. D.1 [see online supporting information]). For example, when the values for HSIL-to-anal cancer progression in untreated and treated patients were 0.001 and 0.003, respectively, do nothing was cost-effective.
The probabilistic sensitivity analysis showed that in 40-year-old HIV-positive MSM, adjuvant qHPV vaccination was cost-effective with a 73% probability at the threshold of $100,000/QALY; alternatively, do nothing was cost-effective with a 27% probability (Supporting 
DISCUSSION
Our comparative analysis of clinical effectiveness and cost-effectiveness shows that active monitoring without treatment until invasive cancer is identified is likely to be the most effective HSIL management strategy for HIVpositive MSM who are 29 years old or younger. In patients who are 30 years old or older, treatment plus adjuvant qHPV vaccination is potentially most effective. However, considering the cost-effectiveness of interventions, we found that do nothing is likely to be costeffective until the age of 38 years, and HSIL treatment along with adjuvant qHPV vaccination is potentially most cost-effective in patients aged 38 years (95% confidence interval, 34-43 years) or older with the commonly used willingness-to-pay threshold of $100,000/QALY. It is neither effective nor cost-effective to treat patients who are 29 years old or younger because of their lower likelihood of developing anal cancer and the higher likelihood of natural regression of HSIL among younger patients. This finding is consistent with the rationale that the incidence of anal cancer increases with increased age 3, 49 ; therefore, the benefits of treatment might be higher in older patients.
In a manner similar to cervical disease in women, the regression of anal HSIL has been shown to be associated with age. Tong et al 27, 50 found that among HIVpositive MSM, the regression rate was significantly lower in men older than 35 years versus those younger than 35 years (P 5 .048). Thus, the findings from our study support a conservative approach of active monitoring in men younger than 35 years, and they would represent an approach comparable to the management of cervical HSIL among young immunocompetent women. 51, 52 For immunocompetent women between the ages of 21 and 25 years, minimum evaluation and management of abnormal cervical cytology are recommended. 51, 52 Our findings could inform the development of similar guidelines for anal HSIL management for preventing overtreatment in younger HIV-positive MSM.
Unlike the management of cervical HSIL, in which cervical abnormalities detected by regular screening can be effectively managed with procedures such as the loop electrosurgery excision procedure, 53 complete ablative management of anal HSIL is difficult and is associated Figure 3 . One-way sensitivity analysis of the age at HSIL diagnosis. ICERs and 95% confidence intervals are shown by the HSIL age at diagnosis. The x-axis represents the age at HSIL diagnosis, and the y-axis represents the willingness-topay threshold. A willingness-to-pay threshold of $100,000/ QALY is considered economically acceptable. HSIL indicates high-grade squamous intraepithelial lesion; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year. with a high rate of recurrence and a higher likelihood of adverse events. 22, 54 Therefore, regular anal cytologybased screening protocols for the detection of these lesions would be unreasonable without the identification of a definitive and cost-effective management strategy for HSIL. 11, [54] [55] [56] Surgical and ablative anal HSIL therapies are not without significant risk. They can be associated not only with additional cost but also with temporary morbidity, including pain, rectal bleeding, and discharge. Long-term complications are rare but can include anal stenosis, fistula and fissure formation, and discomfort with alterations in sexual satisfaction. Therefore, before treatment is recommended, it is crucial for clinicians to consider the risk of progression to invasive cancer, the treatment duration, treatment-related adverse effects, the likelihood that a patient will comply with and adhere to treatment for subsequent lesions, the patient's preference, and the cost of care.
There are several obstacles to developing HSIL management guidelines. For example, compared with cervical colposcopy, HRA along with HSIL management is difficult and involves challenges such as uneven topography and the obscuring of lesions due to anal warts, hemorrhoids, folds, stool, or muscle; lesions may also be located at the base of folds and anal glands. 57 Thus, to adequately screen for and manage HSIL lesions, clinicians often need additional training above and beyond that training specified by even subspecialty medical boards. Our analysis suggests that treating HSIL in HIV-positive MSM is costeffective; however, at this time, the number of clinicians with adequate experience for diagnosing and managing HSIL in HIV-positive individuals in the United States remains inadequate. Therefore, it is imperative to make educational efforts to train clinicians in the requisite procedures.
The National Cancer Institute-supported AIDS Malignancy Consortium has recently launched a phase 3 clinical trial (Anal Cancer/HSIL Outcomes Research [ANCHOR] ) to compare the outcomes of active monitoring via regular examinations and treatment for HSIL. The ANCHOR study will hopefully fill in some of the gaps related to the natural history of HSIL in HIVinfected individuals; however, ensuring cost-effective approaches during the implementation of HSIL screening and management recommendations and guidelines remains of the utmost importance in this day and age of rising health care costs.
Our study is not without limitations. The data, including the effectiveness of HSIL treatment, the effectiveness of adjuvant qHPV vaccination, and the natural history of HSIL, though representing the best available evidence, were obtained from studies that were not randomized and did not directly compare the HSIL management strategies. We addressed this limitation by conducting an extensive sensitivity analysis in which we found that the ICER and the optimal age when treatment plus vaccination becomes effective or cost-effective were most sensitive to HSIL-to-anal cancer progression and HSIL regression among untreated patients. Although observational studies and the Study of Prevention of Anal Cancer Trial have reported HSIL regression, 27,58 the HSIL-to-anal cancer progression rate remains unobserved. Because the outcomes were most sensitive to the HSIL progression rate, which remains the area of greatest uncertainty, our findings should be interpreted within the context of this limitation. Furthermore, in our model calibration, we found that the progression is likely to increase with increasing age. Future research should prioritize the assessment of age-specific HSIL progression and regression, which remain the area of greatest uncertainty. Finally, the objective of our study was to estimate costeffectiveness for the US health care system. According to the costs of HSIL care, anal cancer care, and HIV care and according to the outcomes (eg, recurrence rate and survival), the cost-effectiveness will vary for other health care systems (eg, Canada, the United Kingdom, and Australia).
The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends HPV vaccination for the primary prevention of anal cancer in males aged 11 to 26 years. HPV vaccination is not licensed for males older than 26 years. No data on HPV vaccination efficacy exist for primary prevention in males older than 26 years. We considered posttreatment adjuvant qHPV vaccination as a comparator in these men. This is because there are early data suggesting that men older than 26 years with anal HSIL may have a decreased risk of HSIL recurrence when they are given an adjuvant qHPV vaccine at the time of their HSIL treatment without the addition of any side effects. Others have reported similar evidence for decreasing rates of recurrent cervical intraepithelial neoplasia, vaginal intraepithelial neoplasia, and respiratory and laryngeal papillomatosis. [59] [60] [61] [62] [63] [64] [65] [66] Posttreatment adjuvant vaccination is not completely accepted in clinical practice because of the lack of randomized clinical trial data. Furthermore, it is not understood whether the vaccine prevents the recurrence of the initially treated lesion or halts new HSIL development. Because of these uncertainties, it might be several more years before data Original Article from randomized clinical trials inform this practice for the prevention of anal cancer; however, the implementation of such a strategy sooner rather than later might present an important cancer prevention opportunity. 67 Finally, our results demonstrate that age can be used as an important predictor for the determination of individuals who might benefit more from treatment versus those who may not. Emerging data show that the persistence of HPV-16 or any high-risk HPV might play a role in the lack of HSIL clearance and subsequent progression to anal cancer in HIV-infected individuals. 58 As this association is established, age-specific risk-stratified outcomes of HSIL management must be determined. Likewise, smoking might play a role in the determination of an algorithm for HSIL management. 68 Therefore, the role of smoking on anal cancer's natural history and treatment algorithms needs to be evaluated.
In conclusion, our study is the first to demonstrate that younger HIV-positive MSM might benefit from a conservative approach to HSIL management. Furthermore, posttreatment adjuvant qHPV vaccination is likely to be the most cost-effective strategy for managing HSIL in patients 38 years old or older. Future research needs to prioritize determining the age-specific natural history of anal cancer.
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